Sobour Biopharma

Sobour Biopharma is a clinical-stage biopharmaceutical company headquartered in Shanghai, China, specializing in the discovery and development of novel small molecule therapeutics for oncology and autoimmune disorders. The company's lead candidate, SB-001, is a highly selective TYK2 inhibitor currently undergoing clinical evaluation for inflammatory indications such as psoriasis. Sobour's pipeline also features inhibitors targeting HPK1 and USP1, designed to address unmet needs in cancer immunotherapy and DNA damage response pathways. Founded in 2020, the company is supported by leading life science venture capital firms including Lilly Asia Ventures and Qiming Venture Partners. The firm leverages a robust internal discovery engine to translate complex biological insights into high-value therapeutic candidates.